Profund Advisors LLC Prothena Corp Public LTD CO Transaction History

Profund Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$11.95 - $18.35 $30,484 - $46,810	2,551 Added 20.15%	15,212 $210,000
Q3 2024 Nov 13, 2024	SELL	$16.73 - $24.79 $90,542 - $134,163	-5,412 Reduced 29.95%	12,661 $211,000
Q2 2024 Aug 13, 2024	SELL	$19.54 - $26.15 $562,849 - $753,250	-28,805 Reduced 61.45%	18,073 $373,000
Q1 2024 May 08, 2024	BUY	$24.75 - $40.66 $324,819 - $533,621	13,124 Added 38.88%	46,878 $1.16 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $230,047 - $372,518	7,120 Added 26.73%	33,754 $1.23 Million

Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $216,870 - $323,701	4,585 Added 20.79%	26,634 $1.29 Million
Q2 2023 Aug 10, 2023	SELL	$48.26 - $78.59 $216,301 - $352,240	-4,482 Reduced 16.89%	22,049 $1.51 Million
Q1 2023 May 11, 2023	BUY	$46.97 - $58.27 $1.25 Million - $1.55 Million	26,531 New	26,531 $1.29 Million

216

34.9M

656K

1.12M

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $481M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.